Progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA expression in non-tumor tissues of the human gastrointestinal tract

Hans-Jürg Monstein, Niclas Grahn, Mikael Truedsson, Bodil Ohlsson

AIM: To investigate the expression of gastrin-releasing peptide (GRP) and GRP-receptor mRNA in non-tumor tissues of the human esophagus, gastrointestinal tract, pancreas and gallbladder using molecular biology techniques.

METHODS: Poly A+ mRNA was isolated from total RNA extracts using an automated nucleic acid extractor and, subsequently, converted into single-stranded cDNA (ss-cDNA). PCR amplifications were carried out using gene-specific GRP and GRP-receptor primers. The specificity of the PCR amplicons was further confirmed by Southern blot analyses using gene-specific GRP and GRP-receptor hybridization probes.

RESULTS: Expression of GRP and GRP-receptor mRNA was detected at various levels in nearly all segments of the non-tumor specimens analysed, except the gallbladder. In most of the biopsy specimens, co-expression of both GRP and GRP-receptor mRNA appeared to take place. However, expression of GRP mRNA was more prominent than was GRP-receptor mRNA.

CONCLUSION: GRP and GRP-receptor mRNAs are expressed throughout the gastrointestinal tract and provides information for the future mapping and determination of its physiological importance in normal and tumor cells.

KEY WORDS: Gastrin releasing peptide (GRP); Gastrin-releasing peptide receptor (GRPR); mRNA expression; Morphogenesis; Gastrointestinal tract

INTRODUCTION

Gastrin-releasing peptide (GRP) is a member of the bombesin family of neuropeptides. Bombesin was originally isolated from the skin of the amphibian Bombina bombina, whereas GRP is the homologous peptide in mammals, including humans[7,8]. GRP and GRP-receptor are widely expressed in the central and enteric nervous systems (ENS). GRP is known to stimulate secretion of gastrin, gastric acid,[9] and pancreatic juice[10] and hormones[11,12] to regulate the immune system[13], and to modulate smooth muscle contractility[14]. The direct expression of GRP and its receptor, and thus the exact mechanism behind its actions in gastrointestinal tissues, are only sparsely examined. Immunocytochemistry revealed the expression of GRP in submucosal cells of the ileum[15]. In colon, in vitro autoradiography showed the GRP-receptor expression in the myenteric, but not submucosal, plexus as well as on smooth muscle cells[10]. Examination of mucosal biopsies revealed GRP-receptor mRNA in cells lining the gastric antrum, but not in any other epithelial cells of the gastrointestinal tract[16].

GRP and GRP-receptor are frequently expressed in the gastrointestinal cancer cells, such as gastric adenocarcinoma[17],[18], duodenal cancer[19], and colorectal cancer[20]. Cuttitta et al[20] have demonstrated that human cell lines derived from small-cell lung carcinomas of the lung (SCLC) proliferate in response to autocrine release of GRP. In gastrointestinal tumors, GRP-receptor activation only modestly increased tumor cell proliferation, but regulated tumor cell appearances or differentiation and, therefore, should be considered to act as a morphogen[11,16].

Based on these findings, it appears important to establish whether or not GRP and GRP-receptor mRNAs...
are expressed in non-tumor gastrointestinal tissues. In this study, we analyzed GRP and GRP-receptor mRNA expressions in the human esophagus, gastrointestinal tract, pancreas, and gallbladder by means of a reverse-transcription polymerase chain reaction (RT-PCR) technique and Southern blot analysis of the PCR amplicons.

MATERIALS AND METHODS

mRNA isolation and PCR amplification

The collection, origin and status of full thickness biopsies from the human gastrointestinal tract and surrounding tissues from surgically removed biopsies from patients undergoing surgery for gastric diseases has been described elsewhere in detail.\(^\text{[19]}\). In all, 24 biopsy specimens and two control cDNAs (Table 1) were processed and analyzed for the expression of GRP and GRP-receptor mRNA. In subsequent PCR amplification experiments, mRNA and ss-cDNA preparations used were from a previous study and prepared as described recently.\(^\text{[19]}\).

β-actin amplification was performed in two rounds of PCR (30 and 25 cycles each time, respectively) with the same primers under cycle conditions as described above. Due to the positioning of the primers, cDNA and genomic DNA will yield β-actin fragments of different sizes (288 bp for cDNA and 400 bp for gDNA PCR amplicons, respectively). This allows monitoring for DNA contamination in ss-cDNA preparations and to assess for the integrity of the ss-cDNA used.\(^\text{[19]}\). Control cDNA derived from pancreas and stomach mRNA was purchased from Clontech (BD-Biosciences, Clontech, Stockholm, Sweden).

PCR amplification of GRP and GRP-receptor ss-cDNA

PCR was performed using a HotStarTaq Master mix kit (Qiagen, Hilden, Germany) in a final reaction volume of 25 µL. Each reaction contained 2 µL of the cDNA synthesis reaction as template. Quick-clone human pancreas and stomach cDNA (Clontech, BD Biosciences Stockholm, Sweden) were used as positive PCR amplification controls, whereas HotStar PCR amplification mix without ss-cDNA addition was used as a negative control. PCR amplification conditions, annealing temperature and primers used are shown in Table 2 and were taken from the study by Uchida et al.\(^\text{[20]}\). For increased sensitivity, nested PCR amplifications were carried out for the detection of GRP and GRP-receptor cDNA. First round PCR amplicons were purified using a GFX PCR and Gel Band DNA Purification Kit (Amersham Biosciences, Uppsala, Sweden) and, subsequently, 1 µL was used in a nested PCR amplification. As positive PCR amplification controls, commercially available human stomach and pancreas cDNAs (Clontech, BD Biosciences Stockholm, Sweden) were included in the study. Negative PCR amplification controls (PCR mix without DNA template addition) were included to monitor possible contaminations.

Southern blot analysis of PCR amplicons

PCR amplicons were electrophoretically separated on a
15 g/L agarose gel and Southern blot analysis was performed using 10 pmoles of [32P]-5'-end-labelled nested primers hGRP-SE/2 and hGRP-AS/2 or hGRPR-1/SE and hGRPR-2/AS primers as hybridisation probes (Table 2) under the conditions described elsewhere [19].

RESULTS

Integrity of ss-cDNA

All analyzed ss-cDNA yielded fragments of the expected length (288 bp) after two rounds of β-actin PCR amplification and Southern blot analysis, indicating that the ss-cDNA used was essentially free of DNA contamination [19].

Differential tissue expression of GRP and GRP-receptor mRNA

Initially, first round and nested GRP and GRP–receptor PCR amplification conditions were optimized by means of annealing temperature and cycle conditions using two established, premade PCR amplification mixes (puReTaq Ready-To-Go PCR beads, Amersham Biosciences and HotStarTaq Master mix kit, Qiagen). Essentially, the HotStarTaq Master mix kit was used under the conditions described in Table 2.

Southern blot analysis (one-day exposure) of nested GRP-PCR amplicons derived from ss-cDNA revealed PCR bands of the expected size in 18 of 24 (75%) biopsy specimens and in the human stomach and pancreas control cDNA's. It appeared that GRP-PCR amplicons were similar in size to earlier described GRP-PCR amplicons, derived from alternatively spliced GRP-mRNA [20]. However, no attempts were made to further investigate this point. Furthermore, 11 of 24 (46%) biopsy specimens and the human stomach and pancreas control cDNA yielded GRP-receptor PCR amplicons of the expected size (Figure 1, Table 1). After five-day exposure, an additional 9 of 24 (37%) biopsies yielded weak GRP-receptor PCR amplicons as judged by Southern blot analysis (Table 1), indicating a low level expression of GRP-receptor mRNA. Similarly, two tissues revealed the presence of an extra and larger GRP-receptor PCR amplicon. Its nature has not been further investigated.

No GRP and GRP-receptor PCR amplicons could be detected in the gallbladder tissue, indicating a lack of expression of these mRNAs. However, only one gallbladder biopsy was analyzed and, therefore, the result may not be conclusive since variable GRP and GRP-receptor mRNA expressions were observed in ventricle, duodenum, colon ascendens and rectum biopsies (Figure 1, Table 1). More specifically, GRP mRNA appeared to be expressed in 2 of 4 colon ascendens biopsies. In contrast, a weak band corresponding to GRP-receptor expression was detected in 4 of 4 colon ascendens biopsies. After 5-d exposure, indicating a low level of GRP-receptor mRNA expression in these tissues (data not shown). Remarkably, PCR amplicons corresponding to GRP mRNA expression were detected in 4 of 4 transverse colon and 4 of 4 sigmoid colon biopsies (Figure 1). Similarly, GRP-receptor mRNA seemed to be co-expressed in 3 of 4

Table 2 PCR-primers, expected fragment sizes and PCR amplification conditions

| Primer     | Sequence, 5’ to 3’ orientation | Size in bp | PCR conditions |
|------------|--------------------------------|------------|----------------|
| hGRP-SE/1  | AGTCTCTGCTCTTCCCAGCCTCT        | 558        | 30 55°C        |
| hGRP-AS/1  | GCAGAACTCAGTCTCTAGGGGT          |            |                |
| hGRP-SE/2  | CGTGCTGACCAAGATGATACC           | 349        | 30 62°C        |
| hGRP-AS/2  | TCATTGCTGGTTCAGCTGGG            |            |                |
| hGRPR-SE/1 | AGCCCAGCATAGATCATCATCTC         | 1477       | 30 55°C        |
| hGRPR-AS/1 | AGGGCGCAAATTCAAGGGGCAAT         |            |                |
| hGRPR-SE/2 | CTCCCCGTTAAGATGATGCGG           | 388        | 30 62°C        |
| hGRPR-AS/2 | ATCTTCTACGGGCCATGGAG            |            |                |
| β-actin-SE | GCATGGAGTCCCTGCGCATCCAG         | 288/400    | 30/25 55°C     |
| β-actin-AS | CGTCATACTCCTCCTGCTGATCCA        |            |                |

1Numbers of cycles in first and second round PCR amplifications; 2cDNA and gDNA PCR amplicon sizes, respectively.
transverse colon and 3 of 4 sigmoid colon (Table 1).

**DISCUSSION**

Biopsy specimens were collected from various sites of the human gastrointestinal tract and surrounding tissues. Efforts were made to collect the biopsies from fresh, histologically normal tissues (Table 1). Our results showed that GRP and GRP-receptor mRNAs were widely expressed in the human gastrointestinal tract and surrounding tissues. It is tempting to speculate that the variation in GRP and GRP-receptor mRNA levels observed (Figure 1) may reflect a real-time mRNA expression situation. However, we can not exclude the possibility that artifacts based on sample selection (site of collecting and biopsy sizes) may contribute to the observed mRNA level variations.

Co-expression of GRP and GRP-receptor mRNA in the same tissue as observed could lend support to speculations about the existence of an autocrine and/or paracrine loop. For paracrine signaling, the communicating cells need to be in close proximity in order to establish such loops. Expressions of GRP and its receptor mRNA could be originating from different cell types in opposing parts of the tissue collected. To verify the existence of such an autocrine and/or paracrine loop, cellular co-expression of GRP and GRP-receptor mRNA and its subsequent translation into biologically active proteins must be confirmed. This could be achieved either by in situ hybridization or histochemistry techniques, using GRP and GRP-receptor specific hybridization probes or antibodies, respectively.

In lack of the results of such studies, the physiological importance of GRP and GRP-receptor mRNA expression in gastrointestinal tissues can only be speculated upon. However, based on earlier studies, it seems likely that GRP could act on the human colon via receptors on smooth muscle cells and gastric epithelial cells as well as on cells of the ENS. GRP has been shown to be the primary transmitter of motor neurones to gastric cells. Pharmacological doses of GRP showed a concentration-dependent increase in the rhythmic activity of the ileocecum region and evoked contractions of isolated muscle cells from jejunum. Accordingly, inhibition of endogenous GRP delayed gastric emptying and gallbladder contraction. In contrast, small bowel transit was prolonged by the same antagonist. Thus, the effect on the small intestine may be important for mixing movements and not so much for the peristalsis. In our study, the presence of GRP and its receptor throughout the gastrointestinal tract, in addition to earlier studies that showed no expression of the peptides in the epithelial layer except gastric antrum but on colonic smooth muscle cells and ENS, raises the hypothesis that the peptide may affect the motility along the entire GI tract. This is further underlined by the effects on smooth muscle cells. Disturbed tissue levels of GRP have been described in patients with idiopathic intestinal pseudo-obstruction. The physiology and pathophysiology behind intestinal motility and dysmotility are in many aspects unknown. It is difficult to study the physiological effect of one single peptide alone, as the ENS contains many different peptides with an important balance between them. However, GRP seems to be one of the interesting peptides in the regulation of gastrointestinal motility.

To best of our knowledge, this is the first study that describes the presence of GRP and its receptor in the human pancreas. It is in accordance with the observed effect of GRP on the secretion of pancreatic juice and pancreatic hormones. Earlier animal studies have described that GRP is released from vagal, pancreatic nerves after stimulation, and then acts by binding to a specific member of the 7 transmembrane spanning, G protein-coupled receptor superfamily where activation by GRP-receptors is coupled to phospholipase C and phospholipase D.

We were not able to detect GRP or GRP-receptor mRNA expression in the gallbladder. This may be explained by the fact that only one patient was examined. The earlier described effect of a GRP antagonist to inhibit gallbladder contraction suggests that GRP receptors are expressed in the gallbladder. However, antagonists may antagonise more than one receptor, and the technique in the present study was specifically examining the GRP-receptor, not similar receptors in the same family.

The effect of GRP in gastrointestinal carcinogenesis is unclear. Most of resected colon cancers aberrantly express GRP receptor mRNA, whereas immunohistochemically, less than three-quarters of human tumors express this protein. Furthermore, not all of these receptors are functional when expressed, as only a minor amount of resected human colon cancers have been found to bind bombesin when studied pharmacologically. The discrepancy between GRP-receptor mRNA and protein expression may be due to the frequency with which the coding sequence for this receptor is mutated. Some authors suggest that GRP acts as a mitogen and increases tumor cell proliferation, while others have found that GRP/GRP-receptor co-expression in cancer promotes the development of a well-differentiated phenotype and is therefore more a morphogen than a mitogen. Multiple studies suggest that the presence of these two peptides confers a survival advantage.

In conclusion, GRP and GRP-receptor mRNA appear to be expressed throughout the human gastrointestinal tract. This provides information for the future mapping of GRP and GRP-receptor expression at the cellular level, and thereby further determination of its physiological importance in normal and tumor cells.

**REFERENCES**

1. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001; 22: 689-699
2. McConalogue K, Furness JB. Gastrointestinal neurotransmitters. Baillieres Clin Endocrinol Metab 1994; 8: 51-76
3. Konturek SJ, Zabikiewicz R, Konturek JW, Czarnecki J. Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion. Eur J Pharmacol 2003; 481: 1-14
4. Knuthsen S, Holst JJ, Baldissara FG, Skak-Nielsen T, Poulsen SS, Jensen SL, Nielsen OV. Gastrin-releasing peptide in the human porcine pancreas. Gastroenterology 1987; 92: 1153-1158
5. Wood SM, Jung RT, Webster JD, Ghafei MA, Adrian TE, Yanihara N, Yanihara C, Bloom SR. The effect of the mammalian neuropeptide, gastrin-releasing peptide (GRP), on gastrointestinal and pancreatic hormone secretion in man. Clin Sci (Lond) 1983; 65: 365-371

www.wognito.com
Characterization of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans.  

Am J Physiol 2004; 226: 129-139

Preston SR, Woodhouse LF, Jones-Blackett S, Wyatt JL, Primrose JN. High affinity binding sites for gastrin-releasing peptide on human gastric cancer tissue but not uninvolved normal gastric mucosa.  

Gastroenterology 1996; 111: 1241-1249

Carroll RE, Benya RV. Characterization of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans.  

Mol Pharmacol 2000; 58: 601-607

Carroll RE, Korngold H, Simonsen K, Sorensen P, Borell H. Expression of bombesin and gastrin releasing peptide in human colorectal cancer and normal mucosa.  

Br J Cancer 2000; 82: 124-130

Carroll RE, Ostrovsky D, Lee S, Danilkovich A, Benya RV. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines.  

Mol Pharmacol 2000; 58: 601-607

Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.  

Nature 1985; 316: 823-826

Monstein HJ, Grahm N, Truedsson M, Ohlsson B. Oxytocin and oxytocin-receptor mRNA expression in the human gastrointestinal tract: a polymerase chain reaction study.  

Regul Pept 2004; 119: 39-44

Uchida K, Ohtani Y, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K. Expression of gastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.  

J Cancer Res Clin Oncol 2002; 128: 633-640

Vadokas B, Lutnik FE, Lepsien G, Golenhofen K, Mandrek K. Effects of gastrin-releasing peptide (GRP) on the mechanical activity of the human ileocaecal region in vitro.  

Neuropsychopharmacology 2001; 26: 265-270

Degen LF, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, Larsen F, Beglinger C, Hildebrand P. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit.  

Gastroenterology 2001; 120: 361-368

el-Salhy M, Norrgård O. Colonic neuroendocrine peptide levels in patients with chronic idiopathic slow transit constipation.  

Gastroenterology 1994; 107: 1672-1680

Bombesin family receptor and ligand gene expression in human gastrointestinal epithelial cells.  

Peptides 1997; 18: 663-672

Preston SR, Woodhouse LF, Jones-Blackett S, Wyatt JL, Primrose JN. High affinity binding sites for gastrin-releasing peptide on human gastric cancer and Ménétrier's mucosa.  

Cancer Res 1993; 53: 5090-5092

Carroll RE, Benya RV. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas.  

Peptides 1999; 20: 229-237

Carroll RE, Matkowskyj KA, Chakraborti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans.  

Am J Physiol 1999; 276: C655-C665

Carroll RE, Ostrovsky D, Lee S, Danilkovich A, Benya RV. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines.  

Mol Pharmacol 2000; 58: 601-607

Cutitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.  

Nature 1985; 316: 823-826

Monstein HJ, Grahm N, Truedsson M, Ohlsson B. Oxytocin and oxytocin-receptor mRNA expression in the human gastrointestinal tract: a polymerase chain reaction study.  

Regul Pept 2004; 119: 39-44

Uchida K, Ohtani Y, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K. Expression of gastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.  

J Cancer Res Clin Oncol 2002; 128: 633-640

Vadokas B, Lutnik FE, Lepsien G, Golenhofen K, Mandrek K. Effects of gastrin-releasing peptide (GRP) on the mechanical activity of the human ileocaecal region in vitro.  

Neuropsychopharmacology 2001; 26: 361-368

el-Salhy M, Norrgård O. Colonic neuroendocrine peptide levels in patients with chronic idiopathic slow transit constipation.  

Gastroenterology 1994; 107: 223-230

Gregersen S, Ahren B. Studies on the mechanisms by which gastrin releasing peptide potentiates glucose-induced insulin secretion from mouse islets.  

Pancres 1996; 12: 48-57

Corjay MJ, Dobrzanski DJ, Way JM, Viallet J, Shapira H, Worland P, Sausville EA, Battey JF. Two distinct bombesin receptor subtypes are expressed and functional in human lung adenocarcinoma.  

Cancer Res 1993; 53: 5090-5092

Carroll RE, Benya RV. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas.  

Peptides 1999; 20: 229-237

Carroll RE, By Y, Schonbrunn A. Bombesin receptors in a human colorectal cancer cell line: binding properties and function.  

Cancer Res 1993; 53: 5090-5092

Preston SR, Woodhouse LF, Jones-Blackett S, Wyatt JL, Primrose JN. High affinity binding sites for gastrin-releasing peptide on human gastric cancer and Ménétrier's mucosa.  

Cancer Res 1993; 53: 5090-5092

Carroll RE, Benya RV. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas.  

Peptides 1999; 20: 229-237